Fig. 2.

a Estimated proportion of patients with CDP12 and b estimated proportion of patients achieving NEDA-3 at week 96 in patients with and without lymphopenia. “Without lymphopenia” is defined as all ALCs remained ≥ LLN. “With lymphopenia” is defined as ≥ 1 ALC below the LLN at any time during the study. ALC absolute lymphocyte count, CDP12 confirmed disability progression sustained for 12 weeks per EDSS, EDSS expanded disability status score, LLN lower limit of normal (ALC = 0.91 × 10⁹/L), NEDA-3 no evidence of disease activity-3